AU2018269667B2 - N-substituted indole derivatives - Google Patents

N-substituted indole derivatives Download PDF

Info

Publication number
AU2018269667B2
AU2018269667B2 AU2018269667A AU2018269667A AU2018269667B2 AU 2018269667 B2 AU2018269667 B2 AU 2018269667B2 AU 2018269667 A AU2018269667 A AU 2018269667A AU 2018269667 A AU2018269667 A AU 2018269667A AU 2018269667 B2 AU2018269667 B2 AU 2018269667B2
Authority
AU
Australia
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound according
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018269667A
Other languages
English (en)
Other versions
AU2018269667A1 (en
Inventor
Heinz Fretz
Isabelle Lyothier
Julien Pothier
Sylvia Richard-Bildstein
Thierry Sifferlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AU2018269667A1 publication Critical patent/AU2018269667A1/en
Application granted granted Critical
Publication of AU2018269667B2 publication Critical patent/AU2018269667B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018269667A 2017-05-18 2018-05-17 N-substituted indole derivatives Ceased AU2018269667B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/062008 2017-05-18
EP2017062008 2017-05-18
PCT/EP2018/062865 WO2018210995A1 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Publications (2)

Publication Number Publication Date
AU2018269667A1 AU2018269667A1 (en) 2019-10-24
AU2018269667B2 true AU2018269667B2 (en) 2022-02-03

Family

ID=62186481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018269667A Ceased AU2018269667B2 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Country Status (32)

Country Link
US (2) US20200069686A1 (enExample)
EP (1) EP3625224B1 (enExample)
JP (1) JP7065117B2 (enExample)
KR (1) KR102650756B1 (enExample)
CN (1) CN110621666A (enExample)
AR (1) AR111806A1 (enExample)
AU (1) AU2018269667B2 (enExample)
BR (1) BR112019024114A2 (enExample)
CA (1) CA3063637A1 (enExample)
CL (1) CL2019003257A1 (enExample)
CO (1) CO2019010804A2 (enExample)
CR (1) CR20190567A (enExample)
CY (1) CY1124528T1 (enExample)
DK (1) DK3625224T3 (enExample)
EA (1) EA039630B1 (enExample)
ES (1) ES2894124T3 (enExample)
HR (1) HRP20211532T1 (enExample)
HU (1) HUE056406T2 (enExample)
IL (1) IL270616B (enExample)
LT (1) LT3625224T (enExample)
MA (1) MA49127B1 (enExample)
MX (1) MX394108B (enExample)
PE (1) PE20191787A1 (enExample)
PH (1) PH12019502562B1 (enExample)
PL (1) PL3625224T3 (enExample)
PT (1) PT3625224T (enExample)
RS (1) RS62441B1 (enExample)
SG (1) SG11201908660RA (enExample)
SI (1) SI3625224T1 (enExample)
TW (1) TWI768043B (enExample)
UA (1) UA124748C2 (enExample)
WO (1) WO2018210995A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
HRP20211380T1 (hr) 2017-05-18 2021-11-26 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661896A1 (en) * 2003-08-26 2006-05-31 Teijin Pharma Limited Pyrrolopyrimidinethione derivative
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
WO2012127032A1 (en) * 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528144A (ja) 2000-03-24 2003-09-24 ファーマジーン ラボラトリーズ リミテッド 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
BR0309305A (pt) 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
JP2006506327A (ja) 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
CA2514220C (en) 2003-01-29 2012-02-28 Pharmagene Laboratories Limited Ep4 receptor antagonists
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
ES2327760T3 (es) 2004-05-04 2009-11-03 Raqualia Pharma Inc Compuestos de aril-heteroaril-amida ortosustituidos.
WO2005105732A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP1885722B1 (en) 2005-05-19 2011-11-16 Merck Canada Inc. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
WO2008017164A1 (en) 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
KR101612971B1 (ko) 2008-05-14 2016-04-15 아스테라스 세이야쿠 가부시키가이샤 아미드 화합물
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010032123A1 (en) 2008-09-19 2010-03-25 Biotechnology Research Corporation Limited Triterpenoid compounds and methods of use thereof
AU2009295308A1 (en) 2008-09-25 2010-04-01 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
LT2619182T (lt) 2010-09-21 2017-01-25 Eisai R&D Management Co., Ltd. Farmacinė kompozicija
WO2012043634A1 (ja) 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
KR101760164B1 (ko) 2011-07-04 2017-07-20 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서 사이클릭 아민 유도체
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
RS57406B1 (sr) 2013-06-12 2018-09-28 Kaken Pharmaceutical Co Ltd Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
EA030155B1 (ru) 2013-09-06 2018-06-29 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,2,4-оксадиазола в качестве иммуномодуляторов
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
RS57306B1 (sr) 2013-10-17 2018-08-31 Vertex Pharma Inhibitori dnk-pk
WO2015094902A1 (en) 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
HRP20190793T1 (hr) 2013-12-17 2019-06-28 Eli Lilly & Company Spojevi dimetilbenzojeve kiseline
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
SG11201609770TA (en) 2014-05-23 2016-12-29 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016054807A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TWI852872B (zh) 2015-01-09 2024-08-11 日商小野藥品工業股份有限公司 三環性螺化合物之用途
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
AU2016338679B2 (en) 2015-10-16 2021-05-06 Eisai R&D Management Co., Ltd. EP4 antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661896A1 (en) * 2003-08-26 2006-05-31 Teijin Pharma Limited Pyrrolopyrimidinethione derivative
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
WO2012127032A1 (en) * 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives

Also Published As

Publication number Publication date
IL270616B (en) 2022-01-01
CL2019003257A1 (es) 2020-03-27
CY1124528T1 (el) 2022-07-22
TWI768043B (zh) 2022-06-21
RS62441B1 (sr) 2021-11-30
DK3625224T3 (da) 2021-11-08
SG11201908660RA (en) 2019-10-30
CR20190567A (es) 2020-02-10
CN110621666A (zh) 2019-12-27
KR102650756B1 (ko) 2024-03-22
MX2019013639A (es) 2020-01-21
US20230165859A1 (en) 2023-06-01
HRP20211532T1 (hr) 2022-01-07
PL3625224T3 (pl) 2022-01-10
AU2018269667A1 (en) 2019-10-24
US20200069686A1 (en) 2020-03-05
CA3063637A1 (en) 2018-11-22
MX394108B (es) 2025-03-21
JP7065117B2 (ja) 2022-05-11
PH12019502562B1 (en) 2024-06-14
MA49127B1 (fr) 2022-05-31
EP3625224B1 (en) 2021-08-04
SI3625224T1 (sl) 2021-11-30
PE20191787A1 (es) 2019-12-24
CO2019010804A2 (es) 2019-10-09
PT3625224T (pt) 2021-10-06
PH12019502562A1 (en) 2020-07-20
TW201900637A (zh) 2019-01-01
MA49127A (fr) 2021-05-26
LT3625224T (lt) 2021-10-25
KR20200006589A (ko) 2020-01-20
EA201992679A1 (ru) 2020-05-06
JP2020520359A (ja) 2020-07-09
AR111806A1 (es) 2019-08-21
EP3625224A1 (en) 2020-03-25
WO2018210995A1 (en) 2018-11-22
ES2894124T3 (es) 2022-02-11
HUE056406T2 (hu) 2022-02-28
UA124748C2 (uk) 2021-11-10
EA039630B1 (ru) 2022-02-18
BR112019024114A2 (pt) 2020-06-02

Similar Documents

Publication Publication Date Title
AU2018269667B2 (en) N-substituted indole derivatives
JP2023515235A (ja) ４－アミノブタ－２－エンアミド誘導体及びその塩
US11325899B2 (en) Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
US11446298B2 (en) Pyrimidine derivatives
JP7159214B2 (ja) Ｐｇｅ２レセプター調節剤としてのフェニル誘導体
BR112018010291B1 (pt) Composto, composição farmacêutica, e, uso de um composto
KR102288246B1 (ko) 라파마이신 신호전달 경로 저해제의 기계적 표적 및 이의 치료학적 적용
CN103124731A (zh) 稠合的杂芳基化合物及其应用
HK40020596B (en) N-substituted indole derivatives
HK40020596A (en) N-substituted indole derivatives
WO2025229177A1 (en) Crystalline forms of an n-substituted indole derivative

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired